Analysts predict that Unum Therapeutics Inc (NASDAQ:UMRX) will announce $3.11 million in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Unum Therapeutics’ earnings. The lowest sales estimate is $1.80 million and the highest is $4.41 million. Unum Therapeutics reported sales of $2.04 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 52.5%. The firm is scheduled to report its next quarterly earnings results on Monday, November 11th.
According to Zacks, analysts expect that Unum Therapeutics will report full year sales of $13.85 million for the current year, with estimates ranging from $9.70 million to $17.60 million. For the next year, analysts forecast that the company will post sales of $16.91 million, with estimates ranging from $9.00 million to $25.33 million. Zacks’ sales calculations are an average based on a survey of research analysts that follow Unum Therapeutics.
Unum Therapeutics (NASDAQ:UMRX) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.34) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.05. Unum Therapeutics had a negative net margin of 340.49% and a negative return on equity of 75.60%. The firm had revenue of $3.14 million during the quarter, compared to analyst estimates of $3.10 million.
A number of institutional investors have recently added to or reduced their stakes in UMRX. BlackRock Inc. lifted its position in Unum Therapeutics by 281.5% during the fourth quarter. BlackRock Inc. now owns 1,530,419 shares of the company’s stock valued at $6,733,000 after purchasing an additional 1,129,262 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Unum Therapeutics by 251.5% during the fourth quarter. Bank of New York Mellon Corp now owns 46,248 shares of the company’s stock valued at $204,000 after purchasing an additional 33,091 shares during the last quarter. Northern Trust Corp lifted its position in Unum Therapeutics by 312.6% during the fourth quarter. Northern Trust Corp now owns 178,640 shares of the company’s stock valued at $786,000 after purchasing an additional 135,345 shares during the last quarter. Geode Capital Management LLC lifted its position in Unum Therapeutics by 85.4% during the fourth quarter. Geode Capital Management LLC now owns 132,565 shares of the company’s stock valued at $583,000 after purchasing an additional 61,061 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Unum Therapeutics by 11.6% during the fourth quarter. Bank of America Corp DE now owns 99,545 shares of the company’s stock valued at $438,000 after purchasing an additional 10,317 shares during the last quarter. 47.16% of the stock is owned by institutional investors.
Shares of NASDAQ UMRX traded up $0.25 during midday trading on Friday, hitting $2.00. 32,000 shares of the company’s stock traded hands, compared to its average volume of 131,761. Unum Therapeutics has a 1 year low of $1.50 and a 1 year high of $16.72. The stock has a market capitalization of $55.50 million, a price-to-earnings ratio of -1.44 and a beta of 1.38. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.65 and a current ratio of 2.41. The firm has a fifty day moving average of $2.22 and a 200 day moving average of $3.34.
About Unum Therapeutics
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Read More: How Do You Calculate Return on Equity (ROE)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.